JONES Todd K.

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure, wherein R1 and R2 may be single substit…

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:wherein Rand Rmay be single substituents…

This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…

This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…

This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…

This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…

This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…

This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…

A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …

A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …

A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …

A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …

A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …

A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post …

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single sub…